Where does Global Blood Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Global Blood Therapeutics, Inc. ranks #6,029 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Global Blood Therapeutics, Inc. hold?

Global Blood Therapeutics, Inc. holds 56 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is Global Blood Therapeutics, Inc.'s Innovation Score?

Global Blood Therapeutics, Inc. has an Innovation Score of 38.5 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Global Blood Therapeutics, Inc. focus on?

Global Blood Therapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 52 patents, ranking #151 of 3,165 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Global Blood Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Global Blood Therapeutics, Inc.'s recent grant velocity is -4% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Global Blood Therapeutics, Inc.'s patents?

Global Blood Therapeutics, Inc.'s patents average 17.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Global Blood Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Global Blood Therapeutics, Inc.

USPTO PatentsView assignee record - 56 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Global ranks #6,029 of 49,997 tracked US assignees by granted-patent volume, with 56 patents across 7 technology areas.

#6,029
of 49,997 US assignees by volume: Top 41%
by Innovation Score (38.5/100): 17.1
avg claims per patent: -4%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6029 · US Corporation #6,029 · 56 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 56 grants
UPPER-Q #6,029/49,997
PHOTO-FINISH Fresenius Vial SAS
CPC-NARROW C07D · 7 areas
INNOV-THIN 38.5/100
CLAIMS-RICH 17.1 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT -4% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Fresenius Vial SAS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Global’s 38.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.0 pts (36%) Velocity 4.9 pts (13%) Breadth 9.4 pts (24%) Claim depth 10.3 pts (27%)

Qualcomm Incorporated · highest

85
DigitalOptics Mems · near

39
Frazier Industrial · near

39
Global Blood… · this assignee

39
MAC Trailer… · near

39
Siemens Österreich · near

39
3D Lighting… · lowest

7

What this shows Global's Innovation Score is 38.5/100 (top 41% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Global?

Each dot is one of Global’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Global’s own 17.1 claims/patent is ABOVE the 12.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Global vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Global's grants concentrate

Global Blood Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 92.9% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2018 (10 grants) versus a trough of 2 in 2024. By volume, Global sits between Fresenius Vial SAS and Intersurgical AG.

Global's three-year grant acceleration

Global Blood Therapeutics, Inc. shows 14 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Fresenius Vial SAS

56
Garant GP

56
Grip Holdings

56
Guangzhou China S…

56
Hobart Brothers

56
HP Printing Korea

56
Integrity Implants

56
Intersurgical

56
Global Blood Ther… ◀

56

What this shows Global holds 56 patents at rank #6,031, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Global

By rank, the assignees closest to #6,031 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Global's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Global, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Global ranks #151 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

MAC Trailer Manufacturing, Inc. 39 Frazier Industrial Company 39 DigitalOptics Corporation Mems 39 Siemens AG Österreich 39

Similar claim depth

Nearest assignees by average claims per patent (17.1 here).

RareCyte, Inc. 17.1 avg Thermo Electron Scientific Instruments LLC 17.1 avg St. Jude Medical, LLC 17.1 avg Joby Aero, Inc. 17.1 avg

Global's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 41% higher than 59% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Global Blood Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	5.4%
2016	4	7.1%
2017	5	8.9%
2018	10	17.9%
2019	6	10.7%
2020	9	16.1%
2021	4	7.1%
2022	5	8.9%
2023	7	12.5%
2024	2	3.6%
2025partial year	1	1.8%

Which technologies does Global Blood Therapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 52

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 42

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

C07C - Acyclic OR Carbocyclic Compounds 15

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 4

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 3

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Global Blood Therapeutics, Inc.'s patent record in context - here's where to go next.

Global Blood Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 92.9% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #6,029 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Global Blood Therapeutics, Inc. against Fresenius Vial SAS, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.